Clinical Trial Update: Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial [Phase 3]

View source ↗

Summary

A Phase 3 randomized controlled trial evaluating an angiotensin-converting enzyme inhibitor for early IgA nephropathy with low-to-moderate proteinuria has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Angiotensin-converting enzyme inhibitor (angiotensin-converting enzyme inhibitor)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Biopsy-confirmed IgA Nephropathy, Proteinuria Less Than 0.5 g Per Day | Phase 3 | Status: COMPLETED